Study supports the use of IMNOVID® (pomalidomide) in patients

New oral therapy IMNOVID® (pomalidomide), used in combination with low-dose dexamethasone, has demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM), according to a study in the Lancet Oncology. €œUnfortunately the prognosis for relapsed and refractory multiple myeloma is poor as there are few effective therapeutic options for people living with this disease,€ said Professor Steve Schey, Kings College London, author and UK Principal Investigator of the study.  €œWhile remission is generally achieved after initial treatment, in the majority of cases the cancer returns and these patients relapse, requiring further treatment.